Growing Cannabis Use by Patients Needs to Be Matched by Counseling and Awareness of Risks, Report Says

Growing Cannabis Use by Patients Needs to Be Matched by Counseling and Awareness of Risks, Report Says
As medicinal use of cannabis becomes increasingly accepted among certain patient groups, including people with fibromyalgia, physicians will be progressively pressed to understand its use, effects, limitation and risks to properly inform and guide patients. The main pharmacologically active chemicals in cannabis are the cannabinoids Tetrahydrocannabinol (THC) and cannabidiol (CBD). THC works by binding to and activating the CB1 and CB2 receptors, and is the ingredient responsible for the “high” people experience with the herb. According to a special report, “Contemporary Routes of Cannabis Consumption: A Primer for Clinicians,” published in the Journal of the American Osteopathic Association, researchers are particularly concerned about mental health among medicinal cannabis users, as THC has been shown to induce transient symptoms of psychosis among healthy volunteers and is thought to be a risk factor in developing psychosis. "We have a special concern for young people in their late teens and early twenties, whose brains are still developing," Jeramy Peters, lead study author, said in a press release. Peters and co-author Joseph Chien, both MDs, are with the department of psychiatry at Oregon Health and Science University in Portland. Conversely, CBD is thought to have antipsychotic and anxiolytic properties. Regarding their medical utility, moderate-quality evidence suggests that THC may help chronic neuropathic or cancer pain, and that THC and CBD may benefit patients who have spasticity due
Subscribe or to access all post and page content.